SCHEMBL3688486

SCHEMBL3688486

CCCN(CCOc1ccc2c(ccn2C(C)(C)C(=O)O)c1)S(=O)(=O)c1sc2ccccc2c1C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
SQLE Q14534 2/20 0.33
BCL2 P10415 1/20 0.33
MCL1 Q07820 1/20 0.33
PPARG P37231 5/20 0.32
PPARA Q07869 5/20 0.32
ALK Q9UM73 1/20 0.32
BAZ2B Q9UIF8 1/20 0.32
CXCR2 P25025 1/20 0.32
PTPN7 P35236 1/20 0.32
DUSP3 P51452 1/20 0.32
PTPN12 Q05209 1/20 0.32
PTPN22 Q9Y2R2 1/20 0.32
KCNA5 P22460 1/20 0.32
KCNJ5 P48544 1/20 0.32
KCNJ3 P48549 1/20 0.32
TRPM8 Q7Z2W7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3689331 0.91 PER2 (0.36) PPARGPPARACMA1PPARD
SCHEMBL3689854 0.90 HTR6 (0.40) CMA1
SCHEMBL3683155 0.85 MCL1 (0.34) KDM4EALDH1A1MEN1KMT2AMCL1
SCHEMBL3688162 0.81 ALDH1A1 (0.45) KDM4EALDH1A1PPARGPPARA
SCHEMBL3693027 0.79 PKM (0.38) KDM4EALDH1A1SQLEBAZ2BKCNA5
SCHEMBL3686015 0.77 CMA1 (0.38) KDM4EPPARGPPARACMA1HPGD
SCHEMBL3684613 0.76 PPARG (0.34) PPARGPPARACMA1PPARD
SCHEMBL3690427 0.76 HTR6 (0.41) CMA1
SCHEMBL13509420 0.74 MAPT (0.36) ALDH1A1PPARGPPARAALK
SCHEMBL13508550 0.72 PTPN7 (0.45) PPARGPPARAPTPN7DUSP3PTPN12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
EP-1597248-B1 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS LILLY CO ELI (US) 2007-12-26 EP disclosed
EP-1597248-B1 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS LILLY CO ELI (US) 2007-12-26 EP disclosed
US-20060217433-A1 Sulfonamide derivatives as ppar modulators ELI LILLY AND COMPANY (US) 2006-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217433-A1 Sulfonamide derivatives as ppar modulators PPARD, PPARA, PPARG KDM4E 3238/4885ALDH1A1 1050/4885MEN1 4858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.